NEW HAVEN, Conn.--(BUSINESS WIRE)--Mar. 29, 2013--
(NYSE: COV), a leading global provider of healthcare products, today
announced that it has won a patent infringement suit against Ethicon
Endo-Surgery, Inc., a Johnson & Johnson company, relating to Ethicon's
Harmonic® line of ultrasonic surgical products.
The federal court awarded Covidien a $176.5 million verdict upon ruling
that several claims of Covidien’s patents were valid, enforceable, and
infringed by Ethicon. The amount of the verdict, which could be
appealed, was based on an 8 percent royalty rate on infringing sales
through March 2012, plus prejudgment interest.
“As a global healthcare market leader, Covidien invests significant
resources into creating and developing medical innovations. We are
pleased that the federal court recognized our innovation in ultrasonic
surgical devices, finding our patents both valid and infringed by
Ethicon Endo-Surgery. We will continue to vigorously protect our
innovative products, solutions and intellectual property,” stated Chris
Barry, President, Advanced Surgical Technologies, Covidien.
The federal court found that Ethicon infringed Covidien’s U.S. Patents
6,063,050, 6,468,286, and 6,682,544, each relating to ultrasonic cutting
and coagulation surgical devices.
Covidien is a leading global healthcare products company that creates
innovative medical solutions for better patient outcomes and delivers
value through clinical leadership and excellence. Covidien manufactures,
distributes and services a diverse range of industry-leading product
lines in three segments: Medical Devices, Pharmaceuticals and Medical
Supplies. With 2012 revenue of $11.9 billion, Covidien has 43,000
employees worldwide in 70 countries, and its products are sold in over
140 countries. Please visit www.covidien.com
to learn more about our business.
Marguerite Copel, 203-821-4720
Lannum, CFA, 508-452-4343